Biotech designed to commercialize Ascendis' endocrinology drugs in China files $86M IPO

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 million IPO.

Related Posts

The Patient as Your Guide: Thriving in New Commercial M...

Feb 10, 2025  0

In patent clash over injectable Keytruda, Merck and Hal...

Mar 6, 2025  0

Roche, Gilead top patient groups’ rankings of pharma ES...

Feb 28, 2025  0

Comments

Name

Email

Comment

Post Comment